Flemish Joint Effort for Biomarker PRofiling in Inflammatory Systemic Diseases

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

2500 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-09-28

Study Completion Date

2029-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

A multi-centre, prospective study to study cytokine profiles and other potential disease-specific biomarkers in patients with presumed or confirmed diseases of systemic inflammation

The goal of this prospective, observational study is to describe the longitudinal evolution of blood cytokine profiles in patients with presumed or confirmed diseases of systemic inflammation

The main questions it aims to answer are:

* What are the differences and similarities in blood cytokines between different patients and groups presenting symptoms of systemic inflammatory conditions?
* How is the cytokine profile of individual patients evolving over time and what is the effect of different therapeutics?
* Is cytokine profiling a valuable tool to diagnose and follow-up on patients with systemic inflammatory conditions?

Participants will be asked to give an additional blood volume for research purposes when blood sampling is performed for routine clinical purposes. A subset of patients (those initiated on biologicals) will also be asked to complete questionnaires.

Researchers will compare the blood cytokines profiles between the different groups of systemic inflammatory conditions and with healthy individuals.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Development and Characterization of Functional Assays for the Analysis of Inflammation Signaling Pathways

NCT06971289

Autoinflammatory Disease

NOT_YET_RECRUITING

Molecular Inflammation Board at the Center for Personalized Medicine

NCT07132333

Psoriasis (PsO) Psoriasis Arthritis Inflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis) +1 more

RECRUITING

Immune Dysfunction in Critical Illness: Utility of a Panel of Genes and Molecules Involved in the Immunological Synapse

NCT05954260

Critical Illness

RECRUITING

Evaluation and Long-Term Follow-up of Patients With Inflammatory Disorders

NCT00001351

Inflammation

ENROLLING_BY_INVITATION

A Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Nephrologists

NCT06322641

Atherosclerotic Cardiovascular Disease (ASCVD) Chronic Kidney Disease (CKD) Systemic Inflammation

COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

FEBRIS is a prospective, observational and multi-centric study involving 5 hospitals in Flanders, Belgium.

In this study, the researchers will us ehe FEBRIS Cytokine Profile Assay, which is a multiplex assay measuring pro- and anti-inflammatory cytokines in the blood of subjects. It has been developed in a retrospective cohort of human patients presenting systemic inflammatory disorders.

With this study, the researchers aim to prospectively validate the use of this assay in a cohort of patients that present signs reminiscent of systemic inflammation, including patients with antoinflammatory conditions, autoimmune disorders, hyperinflammatory syndromes (e.g. hemophagocytic lymphohistiocytosis and macrophage activation syndrome) and systemic infection. In parallel, serum amyloid A will be quantified in all patients. Lipidomics will be performed on patients with sufficient leftover sample. The researchers will integrate the data from these assays with clinical parameters at baseline and during follow-up to correlate markers with the clinical or genetic diagnosis, prognosis and effect of different therapeutics.

Patients fulfilling the inclusion criteria are eligible for longitudinal blood sampling (every 3-6 months) during the study period (maximum of 4 years). Additional clotted blood will only be collected when a blood sample for routine clinical purposes is performed.

In addition, patients initiated on biological therapeutics will be asked to complete questionnaires regarding health-related quality of life to document outcome and improve rational and cost-efficient use of additional investigations and treatment.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoinflammatory Disease Autoimmune Diseases Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Pseudonymisation of samples and clinical data for the investigator

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Intervention

Cytokine assessment

Group Type EXPERIMENTAL

cytokine and lipidomic profiling

Intervention Type DIAGNOSTIC_TEST

* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)
* Serum amyloid A
* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases
* Lipidomics

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

cytokine and lipidomic profiling

* FEBRIS Cytokine Profile Assay (quantification of inflammatory cytokines)
* Serum amyloid A
* Biobanking of leftover sample for future analyses and specific immunofunctional assay in selected cases
* Lipidomics

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

An individual who meets any of the following criteria can be eligible for participation in this study:

1. Child or adult
2. Written informed consent
3. Suspected or confirmed disease with systemic inflammation (acute, chronic and/or recurrent), these include:

1. Autoinflammatory diseases (AID), including among others: systemic onset juvenile idiopathic arthritis (sJIA), familial mediterranean fever (FMF), mevalonate kinase deficiency (Hyper IgD syndrome), TNF receptor-associated periodic syndrome (TRAPS), familial Cold Autoinflammatory Syndrome (CAPS), type 1 interferonopathies,…
2. Autoimmune diseases (AI), including among others: systemic lupus erythematosus (SLE), juvenile dermatomyositis (JDM), rheumatoid arthritis (RA),…
3. Hyperinflammatory diseases, including among others: hemophagocytic lymphohistiocytosis (HLH), macrophage activation syndrome (MAS), infection-related cytokine storm (e.g. in the setting of COVID-19)
4. Other unidentified or not yet identified systemic inflammatory conditions
4. Blood sample for diagnostic purposes is planned and possibility to acquire additional blood volume

Exclusion Criteria

An individual who meets any of the following criteria will be excluded from participation in this study:

1. Confirmed localized infection and/or good response to first-line antibiotic treatment
2. Confirmed malignancy

Besides the above mentioned patients, volunteers that meet the requirements as a healthy individual are eligible for inclusion as controls.

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes